GET DAILY SIGNALSMeiraGTx (MGTX) Analyst Price Target of $23 Points to +160% Upside Potential
Key Takeaways
- The central $23 stock price target is the arithmetic mean of eight verifiable analyst price targets, rounded from a calculated mean of $23.13.
- The eight targets reviewed range from $16 (Goldman Sachs) to $35 (Chardan Capital), a wide spread that reflects genuine disagreement about pipeline timelines.
- With shares near $8.79 after a post-earnings decline, reaching $23 would require a roughly 160% advance — a very large move.
- Supporting factors include a cash runway into the second half of 2028 and near-term regulatory catalysts for its bota-vec gene therapy.
- Biggest risks include a recent earnings miss, a still-unprofitable business, clinical and regulatory uncertainty, and potential dilution.
- For more context, explore Major News, Today's Price Move, the Forecast, and Earnings pages on the ticker.
Breaking Down the Analyst Consensus
MeiraGTx Holdings plc (MGTX) is a clinical-stage genetic medicines company developing gene therapies for inherited retinal disease, xerostomia, Parkinson's disease, and other serious conditions. Its analyst price target set is unusually wide, reflecting the binary nature of clinical-stage biotech investing.
Eight named, current targets were reviewed. The low end is Goldman Sachs, which initiated coverage with a Neutral rating and a $16 target in September 2026. The high end is Chardan Capital's $35 (Buy). In between, Piper Sandler holds a $30 target, RBC Capital sits at $27, H.C. Wainwright and Cantor Fitzgerald are both at $20, Bank of America is at $19, and Evercore ISI is at $18. The arithmetic mean of these eight figures is $23.13, which rounds to a central target of $23.
Views split along pipeline-timing lines. More bullish analysts emphasize the bota-vec program for X-linked retinitis pigmentosa and the xerostomia franchise, while the cautious Goldman note reflects a more measured view of near-term commercialization. No single target should be treated as more likely than another; the mean is a statistical midpoint, not a guarantee or a published consensus. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how recent technical shifts align with these views.
Current Market Position and Path Toward the Target
The latest verified price for MGTX is roughly $8.79, following a decline after third-quarter results, with a 52-week range of $6.62 to $15.35 and a market capitalization near $845 million. From $8.79, reaching the $23 central target would require an advance of approximately 160% — a very large move by any standard.
That path would likely depend on executing regulatory milestones rather than ordinary earnings growth. The company expects to submit a Marketing Authorization Application for bota-vec to the EMA (European Medicines Agency) in December 2026, followed by a U.S. BLA (Biologics License Application) in early 2027. The AAV2-hAQP1 program for radiation-induced xerostomia, which holds FDA Breakthrough Therapy Designation, has a Phase 2 data readout expected in mid-2027.
What Could Support a Move Toward the Target
The most meaningful support is the regulatory and clinical catalyst calendar. Approvals or positive data could materially re-rate a stock that trades well below several analysts' sum-of-the-parts views. The company also has a strengthened balance sheet: cash of about $184.7 million at September 30, 2026, plus a $95 million upfront payment due from Hologen, an additional $135 million in potential near-term Lilly milestones, and up to $400 million from Oberland Capital. Management guides that funding reaches into the second half of 2028, reducing immediate dilution risk. A vertically integrated manufacturing footprint and a broad pipeline beyond the lead programs provide optionality.
What Could Prevent the Target From Being Reached
The obstacles are substantial. Third-quarter 2026 revenue of $4.8 million missed estimates near $7 million, and the net loss of $0.53 per share also missed consensus, underscoring that MeiraGTx is still pre-commercial and loss-making. Clinical trials can fail, regulatory filings can be delayed or rejected, and the gene-therapy sector has faced renewed safety scrutiny. As a clinical-stage biotech, the company may still need future equity raises, and dilution would pressure the share count and the per-share path to $23. Technical resistance and the stock's own 52-week high near $15.35 also sit between the current price and the target.
Technical Levels and Market Structure
The 52-week range of $6.62 to $15.35 frames the stock's recent structure. The $6.62 area represents the major support zone, while $15.35 marks the prior high and an important resistance level that would need to be cleared before any move toward $23. A round psychological level near $10 and the $15 area are likely zones where supply could emerge.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though individual horizons vary. The items most relevant to the $23 target are the EMA filing for bota-vec in December 2026, the U.S. BLA in early 2027, the AAV2-hAQP1 Phase 2 readout in mid-2027, progress on the riboswitch and AAV-BDNF obesity programs, analyst target revisions, and any new financing. Quarterly earnings and cash-burn updates will also shape the debate.
Final Assessment
The $23 central target is the rounded mean of eight analyst price targets ranging from $16 to $35. From a recent price near $8.79, it represents a very large required move of roughly 160%. The bullish case rests on regulatory catalysts and a cash runway into 2028, while the bearish case centers on a pre-revenue business model, a recent earnings miss, sector safety concerns, and dilution risk. The wide $16-to-$35 spread shows analysts themselves disagree sharply on the timeline. Whether the stock can reach $23 will depend primarily on successful filings, positive clinical data, and sustained investor confidence in the pipeline — none of which is assured.
Using AI Tools to Track Volatile Names
From what I see in fast-moving sectors like biotech, automated signals add useful context alongside fundamental analysis. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual screening. For investors following volatile names like MGTX, such signals can offer a timely, data-driven complement to fundamental research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MGTX's RSI Indicator ascends from oversold territory
The RSI Indicator for MGTX moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 22 of the 25 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MGTX just turned positive on October 21, 2026. Looking at past instances where MGTX's MACD turned positive, the stock continued to rise in 30 of 40 cases over the following month. The odds of a continued upward trend are 75%.
Following a +2.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGTX advanced for three days, in 213 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
MGTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 56 cases where MGTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MGTX as a result. In 79 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for MGTX entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. MGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.010) is normal, around the industry mean (3.498). P/E Ratio (10.112) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.715) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel treatments for inherited and acquired genetic disorders
Industry Biotechnology
Advertisement